Net revenue rose 23% to $1.39 million with gross margin expanding to 40.2%, driven by B2B distribution growth and reduction in purchase costs ...

New findings highlight the therapy’s ability to preferentially destroy MGMT-positive tumor cells, the specific population that survives standard treatments and drives disease recurrence. TAIPEI, ...

Detailed price information for SL Science Holding Limited (SLBT-Q) from The Globe and Mail including charting and trades.

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. SL Science Holding has experienced a steep share price decline so far this year, ...

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE)-- SL Science Holding Limited ("SL Science" or the "Company") (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative ...

U.S. stock futures were mixed this morning, with the S&P 500 futures falling around 0.1% on Monday. Shares of SL Science Holding Ltd SLBT fell sharply in pre-market trading after the company reported ...

The ODD request was submitted pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb). Product: Vdelta2+ Gamma Delta T CellsDisease / Condition: Glioblastoma Multiforme ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

SL Science Holding Ltd stock reached a 52-week low of $1.74, marking a significant downturn for the company. The stock has plummeted 88% from its 52-week high of $14.50, with the company now carrying ...

Sl Science Hldg's net income for the latest quarter was -1.60. How did Sl Science Hldg's performance compare year-over-year in the latest quarter? The company's revenue moved from 1.22 million USD in ...